De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Rubius Therapeutics Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Craig Jalbert

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.7yrs

Recente managementupdates

Recent updates

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Oct 28

Our Read On Rubius Therapeutics

Jul 11

Rubius Therapeutics EPS beats by $0.02

May 10

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Feb 25

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Rubius Therapeutics EPS misses by $0.01

Nov 09

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

Oct 28

CEO

Craig Jalbert (61 yo)

less than a year

Tenure

Mr. Craig R. Jalbert, CIRA, serves as President, Corporate Secretary, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at Evelo Biosciences, Inc. since November 21,...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Craig Jalbert	President	less than a year	geen gegevens	geen gegevens
Michael Rosenblatt	Independent Director	9.1yrs	US$421.66k	geen gegevens
Robert Langer	Member of Scientific Advisory Board	9.1yrs	US$850.74k	geen gegevens
Harvey Lodish	Scientific Advisory Board	5.9yrs	US$24.00k	geen gegevens
Gerald Nepom	Member of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens
Vijay Kuchroo	Member of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens
Susanne Schaffert	Director	1.5yrs	geen gegevens	geen gegevens
Francis Cuss	Independent Director	6yrs	US$426.66k	geen gegevens
Christopher Carpenter	Member of Scientific Advisory Board	4yrs	US$2.84m	geen gegevens
Christopher Hunter	Member of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens
John Monroe	Member of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RUBY wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.7 jaar), wat duidt op een nieuw bestuur.

Rubius Therapeutics Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Recent updates

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Price target increased to US$7.63

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Price target increased to US$10.33

Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 2000 Growth Index

Rubius: Poor Data, Punishing Environment, Beaten Stock

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Price target decreased to US$7.60

Price target decreased to US$8.67

Price target decreased to US$9.40

Price target increased to US$23.00

Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics, Inc., Annual General Meeting, May 12, 2022

Rubius Looks Attractive Before AACR Data Readout

Price target increased to US$23.00

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Price target decreased to US$21.33

Price target decreased to US$23.33

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Price target decreased to US$25.67

Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Our Read On Rubius Therapeutics

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 3000E Value Index

Rubius Therapeutics, Inc. Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® in Ongoing Phase 1/2 Clinical Trial for Treatment of Advanced Solid Tumors

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Rubius Therapeutics EPS beats by $0.02

Insider exercised options and sold US$313k worth of stock

Rubius Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Announces Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240

New 90-day high: US$15.01

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Price target raised to US$13.25

Executive Chairman notifies of intention to sell stock

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: US$10.00

Price target raised to US$10.29

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Rubius Therapeutics, Inc. Provides an Operational Update

New 90-day high: US$8.83

New 90-day high: US$8.73

New 90-day high: US$5.92

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic Clinical Oncology Program, Rtx-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics EPS misses by $0.01

Rubius Therapeutics, Inc. Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

New 90-day low: US$4.62

Rubius Therapeutics, Inc. Appoints Jose Carmona as Principal Financial Officer, Principal Accounting Officer and Treasurer Effective as of October 1, 2020

New 90-day low: US$4.75

New 90-day low - US$4.81

New 90-day low - US$4.85

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - US$5.46

CEO

Tenure